Literature DB >> 9703961

Prohormone convertase 1 (PC1) when expressed with pro cholecystokinin (pro CCK) in L cells performs three endoproteolytic cleavages which are observed in rat brain and in CCK-expressing endocrine cells in culture, including the production of glycine and arginine extended CCK8.

W Wang1, N P Birch, M C Beinfeld.   

Abstract

Pro CCK was expressed in an L cell line engineered to express PC1 and the products secreted into the media were characterized by a combination of RIA, gel filtration and HPLC. PC1 released from L cells, cleaved pro CCK generating the amino terminal pro peptide. PC1 also generated a peptide which after carboxypeptidase B treatment, was detected with an antiserum specific for CCK Gly. Neither of these peptides was found in media from L cells expressing pro CCK alone. This CCK Gly immunoreactive peptide was similar in size to CCK 8, and after treatment with arylsulfatase and carboxypeptidase B, it co-eluted on HPLC with unsulfated CCK 8 Gly. These results agree with previous studies which support a role for PC1 in generation of CCK 8. This is the first demonstration that PC1 acting alone is able to cleave pro CCK liberating the amino terminal pro peptide and a glycine and arginine extended CCK 8 which is the immediate precursor of CCK 8 amide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703961     DOI: 10.1006/bbrc.1998.9006

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Endocrinomic profile of neurointermediate lobe pituitary prohormone processing in PC1/3- and PC2-Null mice using SELDI-TOF mass spectrometry.

Authors:  Atira Hardiman; Theodore C Friedman; William C Grunwald; Machi Furuta; Ziaorong Zhu; Donald F Steiner; David R Cool
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

Review 2.  PCSK1 Variants and Human Obesity.

Authors:  B Ramos-Molina; M G Martin; I Lindberg
Journal:  Prog Mol Biol Transl Sci       Date:  2016-01-29       Impact factor: 3.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.